Mpi Dmsa Kidney Reagent

Mpi Dmsa Kidney Reagent Brand names, Mpi Dmsa Kidney Reagent Analogs

Mpi Dmsa Kidney Reagent Brand Names Mixture

Didrocal (Calcium Carbonate + Etidronate Disodium)

Mpi Dmsa Kidney Reagent Chemical_Formula

C₉H₁₄N₅O₄P

Mpi Dmsa Kidney Reagent RX_link

http://www.rxlist.com/cgi/generic/viread.htm

Mpi Dmsa Kidney Reagent fda sheet

Mpi_Dmsa_Kidney_Reagent FDA

Mpi Dmsa Kidney Reagent msds (material safety sheet)

Mpi_Dmsa_Kidney_Reagent MSDS

Mpi Dmsa Kidney Reagent Synthesis Reference

No information avaliable

Mpi Dmsa Kidney Reagent Molecular Weight

287.213 g/mol

Mpi Dmsa Kidney Reagent Melting Point

276-280^oC

Mpi Dmsa Kidney Reagent H₂O Solubility

13.4 mg/mL in distilled water at 25°C (disoproxil fumarate salt)

Mpi Dmsa Kidney Reagent State

Solid

Mpi Dmsa Kidney Reagent LogP

0.01

Mpi Dmsa Kidney Reagent Dosage Forms

Tablets for oral administration (300 mg)

Mpi Dmsa Kidney Reagent Indication

For use, in combination with other antiretroviral agents, for the treatment of HIV-1 infection.

Mpi Dmsa Kidney Reagent Pharmacology

Tenofovir belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. Tenofovir is currently in late-stage clinical trials for the treatment of hepatitis B. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.

Mpi Dmsa Kidney Reagent Absorption

The oral bioavailability in fasted patients is approximately 25%. Administration of food (high fat meal containing 40 to 50% fat) increases the oral bioavailability, with an increase in the AUC of approximately 40%.

Mpi Dmsa Kidney Reagent side effects and Toxicity

Limited clinical experience at doses higher than the therapeutic dose of tenofovir 300 mg is available. In Study 901 tenofovir disoproxil fumarate 600 mg was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.

Mpi Dmsa Kidney Reagent Patient Information

Mpi Dmsa Kidney Reagent Organisms Affected

Human immunodeficiency virus